<div id="readability-page-1"><div><ul> <li>Recently, analysts at H.C. Wainwright and Wolfe Research reaffirmed positive views on Corcept Therapeutics, highlighting continued confidence in Korlym and the upcoming launch of relacorilant for Cushing’s syndrome ahead of its December 30, 2025 PDUFA decision, alongside ongoing legal and commercial headwinds.</li> <li>An interesting angle is how enthusiasm around relacorilant’s long-term revenue potential and regulatory milestones is reshaping sentiment even as patent and antitrust disputes remain unresolved.</li> <li>Against this backdrop, we’ll examine how analysts’ optimism around relacorilant’s launch potential and regulatory timeline affects Corcept’s existing investment narrative.</li> </ul><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 22 US stocks have developments that are poised to benefit.</p><h2>Corcept Therapeutics Investment Narrative Recap</h2><p>To own Corcept, you generally have to believe Korlym can fund a transition to a multi‑product business while relacorilant meaningfully broadens the revenue base. The latest bullish analyst commentary around relacorilant’s PDUFA date does not materially change that the key near term catalyst is its December 30, 2025 approval decision, while the biggest risk remains Korlym exposure amid ongoing patent and antitrust disputes.</p> <p>Among recent developments, Corcept’s October update that the FDA accepted relacorilant’s NDA in platinum resistant ovarian cancer, with a July 11, 2026 PDUFA date, is particularly relevant. It frames relacorilant not just as a Cushing’s syndrome asset but as a potential second oncology indication that could further reduce single product dependence if regulatory timelines hold.</p> <p>But while the relacorilant story is gaining momentum, investors should also be aware of how unresolved patent litigation could...</p> <p>Read the full narrative on Corcept Therapeutics (it's free!)</p><p>Corcept Therapeutics' narrative projects $2.0 billion revenue and $743.0 million earnings by 2028.</p><p>Uncover how Corcept Therapeutics' forecasts yield a $134.50 fair value, a 53% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9debd0be-0e12-4a5b-bb89-86d4785ce898/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9debd0be-0e12-4a5b-bb89-86d4785ce898/chart/quote-price"/><figcaption>CORT 1-Year Stock Price Chart</figcaption></figure> <p>Ten members of the Simply Wall St Community now value Corcept between US$74 and about US$260 per share, showing wide disagreement on upside. Set against this, the relacorilant approval timeline remains the central catalyst that could reshape Corcept’s earnings mix and resilience, for better or worse, over the next few years.</p><p>Explore 10 other fair value estimates on Corcept Therapeutics - why the stock might be worth 16% less than the current price!</p><h2>Build Your Own Corcept Therapeutics Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Corcept Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li><li>Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

CORT

<p>Analysts at H.C. Wainwright and Wolfe Research maintain positive views on Corcept Therapeutics, emphasizing confidence in Korlym and relacorilant's potential for Cushing’s syndrome. Despite ongoing legal and commercial challenges, relacorilant's long-term revenue potential and regulatory milestones are reshaping sentiment. The key catalyst is the December 30, 2025 PDUFA decision, with unresolved patent and antitrust disputes posing risks. Corcept's narrative projects $2 billion revenue by 2028, with a fair value estimate of $134.50 per share, indicating a 53% upside.</p>

Does Corcept (CORT) Analysts’ Relacorilant Optimism Outweigh Ongoing Legal And Commercial Uncertainty?